BRPI0413430A - derivados de amida - Google Patents

derivados de amida

Info

Publication number
BRPI0413430A
BRPI0413430A BRPI0413430-3A BRPI0413430A BRPI0413430A BR PI0413430 A BRPI0413430 A BR PI0413430A BR PI0413430 A BRPI0413430 A BR PI0413430A BR PI0413430 A BRPI0413430 A BR PI0413430A
Authority
BR
Brazil
Prior art keywords
infection
caused
chickenpox
medicines
zoster virus
Prior art date
Application number
BRPI0413430-3A
Other languages
English (en)
Inventor
Toru Kontani
Junji Miyata
Wataru Hamaguchi
Tomoaki Kawano
Akio Kamikawa
Hiroshi Suzuki
Kenji Sudo
Original Assignee
Astellas Pharma Inc
Rational Drug Design Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Rational Drug Design Lab filed Critical Astellas Pharma Inc
Publication of BRPI0413430A publication Critical patent/BRPI0413430A/pt
Publication of BRPI0413430B1 publication Critical patent/BRPI0413430B1/pt
Publication of BRPI0413430B8 publication Critical patent/BRPI0413430B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

"DERIVADOS DE AMIDA". O objetivo consiste em se propor um composto inédito útil em medicamentos, especialmente em medicamentos para diversas doenças causadas por infecção com vírus que pretendem à família Herpesviridae, isto é, na prevenção ou tratamento de infecções com diversos herpesvírus, mais especificamente, varicela causada pela infecção com vírus zoster de varicela, herpes zoster causado por infecção repetida com vírus zoster de varicela persistente, herpes labial, e encefalite herpética causada por infecção com HSV1, herpes genital causado por infecção com HSV-2 etc. Um derivado de N-{2-¢(4-fenil substituído)amino!-2-oxoetil} tetraidro-2H-tiopiran-4-carboxamida tendo um substituinte heteroarila específico de 5 ou 6 membros na posição 4 tem uma atividade antiviral favorável e torna possível o tratamento das doenças acima por administração oral de uma pequena dose.
BRPI0413430A 2003-08-08 2004-08-05 derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus. BRPI0413430B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-290850 2003-08-08
JP2003290850 2003-08-08
PCT/JP2004/011573 WO2005014559A1 (ja) 2003-08-08 2004-08-05 アミド誘導体

Publications (3)

Publication Number Publication Date
BRPI0413430A true BRPI0413430A (pt) 2006-10-17
BRPI0413430B1 BRPI0413430B1 (pt) 2019-04-30
BRPI0413430B8 BRPI0413430B8 (pt) 2021-05-25

Family

ID=34114142

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413430A BRPI0413430B8 (pt) 2003-08-08 2004-08-05 derivados de amida os um sal destes, composição farmacêutica compreendendo os mesmos e uso destes para o tratamento de doenças em que está implicado o herpesvírus.

Country Status (19)

Country Link
US (2) US7465748B2 (pt)
EP (1) EP1652843B1 (pt)
JP (1) JP4549974B2 (pt)
KR (1) KR101157074B1 (pt)
CN (1) CN100445271C (pt)
AU (1) AU2004263448B2 (pt)
BR (1) BRPI0413430B8 (pt)
CA (1) CA2535199C (pt)
CY (1) CY1115461T1 (pt)
DK (1) DK1652843T3 (pt)
ES (1) ES2462292T3 (pt)
MX (1) MXPA06001526A (pt)
NO (1) NO335467B1 (pt)
PL (1) PL1652843T3 (pt)
PT (1) PT1652843E (pt)
RU (1) RU2336273C2 (pt)
SI (1) SI1652843T1 (pt)
TW (1) TW200505894A (pt)
WO (1) WO2005014559A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2374236C2 (ru) * 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
AU2003243921B2 (en) * 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
JPWO2006082822A1 (ja) * 2005-02-02 2008-06-26 アステラス製薬株式会社 アシクロビル耐性ヘルペスウイルスによる疾患の予防・治療剤
US20090030049A1 (en) * 2005-02-02 2009-01-29 Astellas Pharma Inc. Medicament for genital herpes
JPWO2006082821A1 (ja) * 2005-02-02 2008-06-26 アステラス製薬株式会社 ヘルペスウイルスが関与する疾患の予防若しくは治療剤
JP5011739B2 (ja) * 2005-02-03 2012-08-29 アステラス製薬株式会社 テトラヒドロ−２ｈ−チオピラン−４−カルボキサミド誘導体を含有する医薬組成物
ES2382815T3 (es) * 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
CA2614518A1 (en) * 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
US8138185B2 (en) * 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
US8318778B2 (en) * 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
DE102008014523A1 (de) * 2008-03-15 2009-09-17 Robert Bosch Gmbh Heizgerät
JP5381978B2 (ja) * 2008-04-02 2014-01-08 アステラス製薬株式会社 アミド誘導体含有医薬組成物
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
EP2351565A1 (en) 2008-10-20 2011-08-03 Astellas Pharma Inc. Medicine for preventing or treating pain related to herpes zoster
CN108623577B (zh) * 2018-05-08 2020-09-25 山东百诺医药股份有限公司 阿莫奈韦及其中间体的制备方法
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
WO2020038812A1 (en) * 2018-08-20 2020-02-27 Rijksuniversiteit Groningen New process for the preparation of amenamevir
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
ATE227279T1 (de) 1995-12-29 2002-11-15 Boehringer Ingelheim Pharma Phenyl thiazol derivate mit antiherpesvirus eigenschaften
AU3289299A (en) * 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
JP2002539119A (ja) * 1999-03-08 2002-11-19 バイエル アクチェンゲゼルシャフト チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用
JP2003500376A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
CN1473157A (zh) 2000-11-10 2004-02-04 ֮����ҩ��ʽ���� 酰胺衍生物
DE10139060A1 (de) 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate
AU2003235889A1 (en) 2002-05-09 2003-11-11 Rational Drug Design Laboratories Amide derivatives
TW200505894A (en) * 2003-08-08 2005-02-16 Yamanouchi Pharma Co Ltd Tetrahydro-2H-thiopyran-4-carboxamide derivative

Also Published As

Publication number Publication date
US6903125B2 (en) 2005-06-07
CY1115461T1 (el) 2017-01-04
AU2004263448A1 (en) 2005-02-17
EP1652843A4 (en) 2010-07-28
KR101157074B1 (ko) 2012-06-22
US20050032855A1 (en) 2005-02-10
PL1652843T3 (pl) 2014-09-30
SI1652843T1 (sl) 2014-06-30
EP1652843B1 (en) 2014-04-02
US7465748B2 (en) 2008-12-16
NO335467B1 (no) 2014-12-15
PT1652843E (pt) 2014-06-02
CN100445271C (zh) 2008-12-24
CA2535199C (en) 2010-12-14
RU2336273C2 (ru) 2008-10-20
WO2005014559A1 (ja) 2005-02-17
TWI341311B (pt) 2011-05-01
TW200505894A (en) 2005-02-16
ES2462292T3 (es) 2014-05-22
BRPI0413430B1 (pt) 2019-04-30
JPWO2005014559A1 (ja) 2006-10-05
AU2004263448B2 (en) 2009-02-05
BRPI0413430B8 (pt) 2021-05-25
CN1832930A (zh) 2006-09-13
JP4549974B2 (ja) 2010-09-22
NO20061100L (no) 2006-03-07
CA2535199A1 (en) 2005-02-17
MXPA06001526A (es) 2006-05-25
RU2006106922A (ru) 2006-08-27
DK1652843T3 (da) 2014-05-05
US20060229295A1 (en) 2006-10-12
KR20060073928A (ko) 2006-06-29
EP1652843A1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
BRPI0413430A (pt) derivados de amida
US4757088A (en) Antiviral pharmaceutical preparations and methods for their use
US5405850A (en) Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative
Bacon et al. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir
BR112022017209A2 (pt) Uso de composto nucleosídeo no tratamento de doenças infecciosas por coronavírus
DE60112790D1 (de) Amidderivate
Thieulent et al. Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: Efficacy of decitabine and valganciclovir alone or in combination
Ahmad et al. Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds
Marcelletti Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs
JPS60202822A (ja) 抗ウイルス薬
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
Maudgal et al. Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.
ATE236923T1 (de) Arabinosyladenin-derivative
EP0101441B1 (en) Anti-viral compositions
Hayashi et al. In vitro and in vivo evaluation of a novel antiherpetic flavonoid, 4′-phenylflavone, and its synergistic actions with acyclovir
Rapp et al. Synergistic effect of human leukocyte interferon and nonoxynol 9 against herpes simplex virus type 2
DK2374461T3 (en) Piroxicam for the prophylactic and therapeutic treatment of herpes infections
Connell et al. Synergistic activity of combinations of recombinant human alpha interferon and acyclovir, administered concomitantly and in sequence, against a lethal herpes simplex virus type 1 infection in mice
DE69510582D1 (de) Purinderivate und ihre pharmazeutisch akzeptablen Salze
Van Bijsterveld et al. Bromovinyldeoxyuridine and interferon treatment in ulcerative herpetic keratitis: a double masked study.
Mastikova et al. Antiviral activity of dipyridamole in experimental viral infections in mice
Centifanto et al. 9-(2-hydroxyethoxymethyl) guanine as an inhibitor of herpes simplex virus replication.
EP1239923A2 (en) Stabilized veterinary compositions comprising more than one antiviral agent
CA2150671C (en) Compositions containing acyclovir-like compounds and 2'-vinyl substituted nucleoside analogs for the treatment of viral infections
EP1844776A4 (en) AGENT FOR THE PREVENTION / TREATMENT OF A DISEASE CAUSED BY A HERPES ACYCLOVIR-RESISTANT VIRUS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: ASTELLAS PHARMA INC. (JP) , RATIONAL DRUG DESIGN L

B25A Requested transfer of rights approved

Owner name: ASTELLAS PHARMA INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2846 DE 22/07/2025 POR TER SIDO INDEVIDA.